923P - The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Lymphomas
Pathology/Molecular Biology
Basic Scientific Principles
Presenter Iryna Kryachok
Citation Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375
Authors I. Kryachok1, A.V. Martynchyk1, K. Filonenko1, A.N. Grabovoy2, S.A. Antoniuk2, I. Tytorenko1, O. Novosad1, T. Kadnikova1, O. Aleksik1, I. Stepanishyna1
  • 1Oncohematology With Adjuvant Chemotherapy, National Cancer Institute of the MPH Ukraine, 03022 - Kiev/UA
  • 2Department Of The Pathological Anatomy And Histology, National Cancer Institute of the MPH Ukraine, 03022 - Kiev/UA



Diffuse large B-cell lymphoma (DLBCL) is a potentially curable disease, but the first line of therapy is not effective for 40% of patients, and new markers for prognosis are needed. Immunohistochemistry (IHC) markers commonly used for lymphomas diagnosing may have predictive significance. There are some publications regarding predictive and prognostic roles of IHC expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30, but their results are controversial.


The retrospective analysis of IHC expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in 267 DLBCL patients was done. Patients were treated at the National Cancer Institute since 2011 and received first-line CHOP-like chemotherapy.


There was positive expression of Bcl-2 in 84% of patients, positive expression of Bcl-6 – in 63%, positive expression of MUM1 – in 62%, positive expression of CD10 – in 39% and positive CD30 expression was determined in 26% of patients with DLBCL. There were 43 patients (16%) with primary-refractory disease and 224 patients (84%) with at least a partial response to first-line therapy. We analyzed the expression of IHC markers in patients who responded to first-line treatment ("R") compared to the expression in primary refractory patients ("PR"). There were no significant differences in the positive expression of such markers as Bcl-2, MUM1 and CD30 between groups "R" and the "PR" (84.7% vs 82.1%, 60.2% vs 66.7%; 23.3% vs 25.0%, p > 0.05, respectively). There was a trend toward more frequent positive expression of CD10 in the "R" group: 44.3% vs 28.6%, p > 0.05. The positive expression of Bcl-6 was significantly more common in the “R” group in comparison with a "PR" group (69.9% vs 38.1%, p 


Positive expression of Bcl-6 is significantly more common in patients who responded to first line treatment. It may indicate the predictive value of this biomarker for identifying the group of patients who respond to the first line therapy.

Clinical trial identification

Legal entity responsible for the study



National Cancer Institute


All authors have declared no conflicts of interest.